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Abstract: The recent development of bone-on-chips (BOCs) holds the main advantage of requiring
a low quantity of cells and material, compared to traditional In Vitro models. By incorporating
hydrogels within BOCs, the culture system moved to a three dimensional culture environment for
cells which is more representative of bone tissue matrix and function. The fundamental components
of hydrogel-based BOCs, namely the cellular sources, the hydrogel and the culture chamber, have
been tuned to mimic the hematopoietic niche in the bone aspirate marrow, cancer bone metastasis
and osteo/chondrogenic differentiation. In this review, we examine the entire process of developing
hydrogel-based BOCs to model In Vitro a patient specific situation. First, we provide bone biological
understanding for BOCs design and then how hydrogel structural and mechanical properties can
be tuned to meet those requirements. This is followed by a review on hydrogel-based BOCs,
developed in the last 10 years, in terms of culture chamber design, hydrogel and cell source used.
Finally, we provide guidelines for the definition of personalized pathological and physiological
bone microenvironments. This review covers the information on bone, hydrogel and BOC that are
required to develop personalized therapies for bone disease, by recreating clinically relevant scenarii
in miniaturized devices.
Keywords: bone-on-chip; bone microenvironment; bone hydrogels; tunable hydrogels; microfluidic
bone treatments; bone models
1. Introduction
Musculoskeletal disorders and related bone diseases are one of the major causes of
pain and disability as well as a social and economical burden for our society. Diseases such
as osteoarthritis, bone fracture, osteoporosis, bone tumor and osteosarcopenia affect 1 of
2 adults in United States [1] and more than 100 million Europeans [2]. More specifically on
bone alteration, the estimated incidence of bone fractures is 3 per 100 people per year in
UK [3] and US [4]. Despite the intrinsic repair capacities of bone tissue, 5–10% of fractures
are not self-healdling and described as non-unions and require expensive operative
interventions [5]. Bone traumatic injuries cost $56 billion every year in US alone [4], while
fractures associated to osteoporosis cost €37.5 billion in the largest European countries [6].
In search of reducing the societal and economical burden of bone diseases, experimental
models of bone tissue are continuously evolving to recapitulate specific mechanisms of bone
physiology, pathology or to evaluate the effect of potential therapies. Two types of models
are available, ex vivo models where bone tissue are cultured outside of the body [7] and
in vitro models where cells are isolated and cultured in a 2D or 3D environment. In vitro
experimental bone models are more easily available than living explants and facilitate
the culture of human cells in a controlled environment outside of living organisms [8].
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Moreover, a high number of parameters can be tested with one single batch. Yet, traditional
2D in vitro models are not suitable for long-term studies and may fail in recapitulating a
clinically relevant environment due to the absence of all factors present in vivo [9], but their
high output and outcome balance this weakness.
The lack of clinical relevance of 2D or the experimental challenge of large scale 3D
in vitro models, which includes the high number of cells necessary and necrosis in the
core of large scaffold, led to the development of the organ-on-chip field. The organ-on-
chip technologies have recently emerged from the synergy of microfabrication techniques
and tissue engineering, aiming to replicate specific processes of organ functionality in
sophisticated in vitro microenvironments and reduce the amount of cells required. While
the use of organ-on-chips for drug screening is steadily increasing [10], the combination of
microengineered systems with primary patient cells is inspiring the field of regenerative
medicine [11] as well as personalized medicine, since they facilitate the use of cells isolated
from individual patients [12]. Different organ-on-chips were recently developed to predict
the variability between individuals associated to specific biological processes, such as the
permeability of the blood-brain barrier [13], the inflammation of the human airways [14],
the proliferation of multiple myeloma cells [15] and the drug-induced hematotoxicity [16].
Compared to other tissues, Bone-On-Chip (BOC) platforms have mostly emerged in
recent years. The first literature review on the development and challenges of BOC systems
has been recently published, showing the main technical solutions adopted to study bone
cell function, bone regeneration and its interaction with multiple tissues [17]. Starting
from a monolayer of mouse osteocyte-like cell line to study mechano-regulation under
oscillatory fluid flow [18], BOCs moved to three dimensional (3D) culture systems that
investigated the osteocytic network formation [19,20] or the bone matrix mineralization
process [21]. Indeed, 3D culture environments mimicking the extracellular matrix (ECM)
provide representative systems of tissue function where hydrogels are an ideal candidate
to reflect the matrix topography and properties. The focus of this specific review is to
describe the entire process to design BOC and to provide an informed perspective of the
type and characteristic of hydrogels and cellular environment required to reproduce a
disease state. First, we describe fundamental aspects of bone physiology and pathology,
thus defining the biological context and requirements for BOCs. Second, we present the
main hydrogels used to mimic the extracellular environment and possible techniques to
tune their structural and mechanical properties. Later, we discuss hydrogel-based BOC
platforms, developed in the last 10 years, in terms of cell source, design of the culture
chamber and hydrogel used. Finally, we provide guidelines on how a BOC should meet
the biological requirements by tuning the hydrogel mechanical properties, while keeping a
strong focus on the development of devices for personalized medicine.
2. Bone Tissue Microenvironment and Pathologies
Skeletal growth and mineral acquisition predominate over the first two decades of
the life of an individual. Over the subsequent decades, the skeleton continues to remodel
with a balance between bone formation and resorption, but more gradually due to aging
factors, metabolic disorders or pathology the remodeling of bone is altered and results in
a decreased resistance to stress (Figure 1). Bone cells modify the tissue mineral content,
quality and composition of the matrix, architecture, and shape in response to growth,
physical forces, and trauma over the life span [22]. Bone also adapts to transient needs,
for example, pregnancy and lactation produce reversible changes in the mineral content
of the skeleton and in the mechanosensation. Indeed osteocytes in fibulae from lactating
mice have larger lacunae which induces stronger response to mechanical loading with
a decrease of Sost expression and an increase of β catenin compared to those from virgin
mice [23].
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Figure 1. Parameters influencing bone remodeling. Human cortical bone is formed of Haversian
canals surrounding by concentric lamellae and form osteons that are bond together by cement line.
During ageing or due to several diseases there is an imbalance of the remodeling which changes the
capacity of cells to respond to a treatment or support the osteointegration of an implant.
2.1. Bone Microenvironment
2.1.1. Tissue
Bone is a vascularised and innervated tissue that provides structural support for the
body and transmits movements that are driven by muscle contractions. The tissue is the
home for the aspirate marrow and the niche of stem cells capable of differentiating into
bone cells, blood cells and in cells from the immune system. Long bones are composed of
spongious bone (trabecular) and of cortical bone which forms a shell around the marrow.
At the macroscale, the organisation of the matrix of long bone provides sufficient load-
bearing capacity to accommodate the daily loads applied to the tissue. In humans, cortical
bone is formed of osteons that are bound with cement line and are highly organized with
a central Haversian canal that contains blood vessels and nerves and are surrounded by
concentric lamellae of bone matrix. Within this matrix, dendritic cells, osteocytes are
trapped in lacunae and form a highly interconnected network of canaliculi [24]. Those cells
are considered the orchestrators of bone homeostasis and mechanosensation which permit
the cells to response to mechanical stimulation. In fact, higher stress on bone increases
bone formation while a significant decrease, as experienced during a space flight, reduces
bone mass [25].
2.1.2. Matrix
The bone matrix is highly organised and surrounds osteocytes. Type I collagen com-
poses 90% of the matrix and gives its toughness to the bone. Other non-collagenous
proteins are present and essential to maintain the calcium within bone for the formation
of hydroxyapatite (HA) crystals and contribute to the cohesion of the matrix. Indeed,
osteocalcin, osteopontin and fibronectin are key proteins that facilitate the mineralization
of the bone and increase its compliance. Bonds between collagen molecules are formed by
enzymatic (lysyl oxidase) and non-enzymatic reactions such as oxidation. Those reactions
can form unspecific bonds that accumulate during ageing in the bone matrix. Water com-
poses about 10–20% of the volume of cortical bone and has a role in dissipating energy by
reducing shear stress and interfaces within the tissue. This water can be free or bound to
matrix component as glycosaminoglycans (GAGs) which correlates positively with bone
toughness [26]. In the embryo, the matrix is produced by bone cells with the process of
modelling and it is constantly renewed during the adult life through the remodeling.
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2.1.3. Bone Cells
Bone homeostasis is regulated by three type of cells: osteoblasts, osteocytes and
osteoclasts. Their activities are regulated in response to variations in external loads and
biochemical factors to adapt the tissue properties to those stimuli. Osteoblasts differentiate
from the Mesenchymal Stem Cells (MSCs) present in the marrow of long bones. They
produce the ECM and differentiate through the osteogenic pathway into osteocytes when
they are surrounded by their own matrix. Osteoclasts are the bone resorbing cells. They
are multinucleated cells formed from the fusion of differentiated cells from hematopoietic
stem cells and remove the old or damaged bone matrix. Both of those cells are regulated
by paracrine factors produced by osteocytes [24]. The factors released stimulate osteoblasts
with osteoprogerin, and the osteoclasts with Sost and RANKL, to repair microdamage or
renew the bone tissue in Bone Modelling Unit (BMU) [27]. These cells are embedded within
the matrix and have a dendritic shape with mechanosensors present on the membrane
extensions (i.e., integrins) which make them capable of sensing the shear stress induced
by the movement of the extracellular liquid. The tri-dimensional shape of osteocytes
is essential when considering in vitro culture as their culture in a 2D flat surface will
dedifferentiate them into osteoblasts and thus change their response to stimuli [28]. When
microdamage occurs, the disruption of dendrites induce the apoptosis of cells with an
increase of caspase-3 within the cytoplasm and an activation of RANKL expression by
the nearby cells which active pathways to remodel the damaged area [29]. MSCs are
multipotent cells present in the bone marrow and have a major role in bone remodeling.
In addition they have therapeutic interest for tissue engineering as they have the capacity
to differentiate into several cell phenotypes, and for cell therapy to treat the inflammation
for example [30].
2.1.4. Microenvironment of Cells
Physico-Biochemical
Within the bone, cells are in contact with a specific ECM that is highly organised and
modifies the physical environment with a specific topography due to the different proteins
of the matrix. This microenvironment changes with ageing or during some pathologies
such as osteoporosis or type 2 diabetes. Indeed the high level of glucose creates aspecific
non-enzymatic cross-links between proteins, called AGE (Advanced Glycation End point)
which alter the mechanical properties of the tissues [31] and induces the apoptosis of
osteoblastic cell lines [32]. Also, the biochemical environment of bone cells is modified
in some specific conditions. Indeed the pH in BMU is affected by osteoclasts as they are
activated with an acidic pH (pH 7) which increases HA solubility and ultimately increase
bone resorption [33].
Mechanical
The daily loads induce strain on the matrix that is transmitted to cells and act as
one of the main activator of pathways implicated in bone metabolism [34]. As the fluid
within the extracellular space is also subjected to the loading, it induces shear stress on the
cell membrane and induces hydrostatic pressure as the system is confined. At the level
of cells, fluid shear stresses induced within the network of osteocytes within the cortical
bone has an average of 1 Pa around rat osteocytes in vivo [35] or within the marrow from
1.67 to 24.55 Pa during cyclic loading of porcine femurs [36]. Several studies have looked
at the effect of shear stress on MSCs and bone cells on their mechanotransduction. Indeed
in vitro application of oscillatory fluid flow to MSCs elicits a significant increase in collagen
and mineral deposition when compared to static control demonstrating that mechanical
stimuli within the marrow is sufficient to drive the osteogenesis [37]. Hydrostatic pressure
is one important mechanical strain in bone during the different active phases of the day,
with an estimation from 0 to 18 MPa during a walk at 1 Hz within the lacunar–canalicular
network [38]. In addition it has been shown that daily application of physiological hy-
drostatic pressure on MSC aggregates accelerates the formation of a mature mineralized
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bone tissue with the presence of bone specific protein (BSP2) [39] and the differentiation of
osteoblast-like cells into osteocytes [40].
2.2. Bone Pathologies
2.2.1. Non-Union Fracture
Bone fracture or osteotomy are common and may prevent spontaneous healing with-
out surgical repair and the use of scaffold or biomedical implants. The healing of such
defects involved a series of four stages: formation of a hematoma, a soft callus, a hard callus
and the remodeling of the matrix. The first 3 stages take place during the initial 3–4 weeks
after which remodeling will occur for months or even years to regain a similar structure
to the pre-fractured bone. During those phases the stiffness of the matrix goes from soft
to high due to the formation a temporary template and then a mineralized matrix, which
ultimately increase the energy of absorption to failure [41]. The composition of the callus
varied from clotted blood with fibrin to fibrocartilage tissues, then first bone trabeculae are
appearing in the callus until the union is formed.
2.2.2. Osteoporosis
Osteoporosis is a debilitating disease that is characterised by a decrease of the Bone
Mineral Density that leads to a more brittle bone. Recently several studies have shown that
shortly after the withdrawn of estrogen from the culture media of bone cells, osteoblasts
release pro-osteoclast factors (RANKL) [42] and differentiate into a later stage of the os-
teogenic pathway [43]. Also estrogen deprivated osteocytes alters αvβ3 expression which
results in downstream signalling in osteocytes during post-menopausal osteoporosis [44].
All together those results showed a hyperstimulation of bone cells during estrogen defi-
ciency which can be counteract by the inhibition of the actin cytoskeleton with an inhibitor
of ROCK [43,45]. It makes the stiffness of the matrix surrounding bone cells a potential
major factor for driving bone homeostasis in post-menopausal osteoporosis. In in vivo
models of postmenopausal osteoporosis it has also been shown as well that secondary
mineralisation occured at a late stage which might make the bone less compliant and more
brittle, and explain the fragility of bone [46]. In addition the variability of phenotype
between individual shown a limitation in predicting overall the outcome of osteoporosis
when the trabecula thickness is thinner before the diseases is installed [47].
2.2.3. Type 2 Diabetes
During Type 2 Diabetes Mellitus (T2DM) it is know that the prevalence of fracture
increases in both males and females [48]. However, it is not fully understood how the
bone is affected as several studies show that patients have DEXA scores with similar or
higher bone mineral density. Some evidence are pointing out changes at the microscale
level where the mineralization of cancellous bone is significantly more heterogeneous
(+26%) in patients presenting with T2DM compared to osteoarthritic controls with a
significant increase of low mineral density bone volume [49]. In addition, it is know that
bone mechanical properties are altered by a high glucose exposition which induces an
increase of the formation of Advanced Glycation End produced (AGE) and the propensity
of cancellous bone to fracture [50]. Although at the nanolevel, the increase of fracture
could be explained by the low affinity of glycated osteocalcin to the hydroxyapatite crystal
surface which decreases the capacity of osteocalcin to dissipate the energy and could make
the bone more brittle [51]. In addition, the glycation of proteins not only affects bone
quality but as well the blood vessels physiology and formation which limits the capacity
for fracture healing, particularly for large defects [52] and alters the physiology of bone
cells [53]. Indeed, ECM glycation alters their connection with cells via the integrins to
the matrix which modify the physiology of cellular growth, proliferation, migration, cell
signalling pathways, and bone remodelling.
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2.2.4. Bone Metastasis
Bone is one of the most common sites for breast cancer metastasis which has a direct
impact of the survival of cancer patients. Indeed 22% of women with breast cancer de-
veloped bone metastasis with a median survival of 2.3 years [54]. Breast cancer cells that
metastasize to bone often target the axial skeleton where trabecular bone is found in the
bone marrow [55]. When metastatic breast cancer cells pass through blood vessels wall and
engraft in trabecular bone, they face a unique mechanical environment that may affect their
progression. The microenvironment is soft with rigid struts of bone matrix. These changes
of stiffness and mechanical stimulation were simulated in vitro by Curtis et al on a breast
cancer cell line, 4T1, laden in a gelatin scaffold and showed changes in the proliferation
and protein expression (PTHrP and OPN) within soft materials with mechanical properties
similar to bone marrow [56]. This showed evidence of mechanosensitivity of cancerous
cells to their microenvironment.
3. Hydrogels
Hydrogels are three-dimensional cross-linked polymer networks produced by the
simple reaction of one or more monomers that, due to their hydrophilic nature, can absorb
large quantities of water. Hydrogels -widely used as models of the ECM- have received
considerable attention in recent years for tissue engineering and regenerative medicine
applications, as they can be designed with controllable responses and because of their
specific properties such as swelling in aqueous medium, their sensitivity to pH, temperature
or other stimuli [57]. However, a throughout knowledge of the properties of hydrogels and
of the structure-property relationships is required in order to select the most appropriate
material for a specific application.
3.1. Classification of Hydrogels
Hydrogels can be classified according to several criteria such as the nature of their
macromolecular structure, on the final form of the system, or on the nature of the
crosslinks [58]. Based on the nature of their macromolecular structure, hydrogels can
be classified as natural, synthetic or hybrid.
Natural polymeric hydrogels are gelsmade from polymers that have a natural origin
such as collagen, fibrin, chitosan, hyaluronic acid or alginate, and have been successfully
employed for tissue engineering applications due to their biocompatibility, biodegradability
and non-toxicity [59]. However, their mechanical strength is poor and their composition
may vary from batch to batch. On the other hand, synthetic hydrogels are synthesized
using synthetic polymers such as methacrylated gelatin, pluronic, or polyethylene glycol
(PEG). Synthetic hydrogels have gradually replaced over the last years natural ones as it is
easier to control physical and chemical properties than for natural polymers (i.e., matrix
elasticity, ligand density and porosity) [60]. However, normal cellular processes, such as
morphology changes, migration and proliferation, are inhibited in synthetic hydrogels
unless they are designed to degrade over time. In fact, non-degradable hydrogels present
typically a pure elastic mechanical behavior, while reconstituted ECMs, such as collagen
or fibrin, are viscoelastic and exhibit a partial stress relaxation when a constant stress is
applied [61] (Figure 2A). This explain the great effort made in the last years to develop
a new class of synthetic hydrogels capable to not only reproduce the molecular stiffness
but also the strain-stiffening and the extent of bundling, such as the thermo-responsive
biomimetic polyisocyanopeptide (PIC) hydrogels [62].
Simultaneously, the lack of adequate mechanical strength of most natural polymers,
have made researchers to develop hybrid scaffolds by combining various hydrogels with
other components to improve their resistance to stress. For this, nanomaterials, biological
factors, and combinations of biopolymers (e.g., proteins and polysaccharide) are added
to hydrogels to produce Interpenetrating Networks (IPNs) and Soft Network Composites
(SNCs), often referred as composite or hybrid hydrogels [63].
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A Mechanical properties B Structural properties Bone-On-ChipC
Collagen 2mg/ml
Collagen 4mg/ml
D Effect of cell encapsulation
Far from the cellNear the cell
Figure 2. Hydrogels for bone-on-a-chip applications. (A) Hydrogel mechanical properties as a func-
tion of network concentration. Scheme of a collagen hydrogel in the rheometer (left). Stress sweeps
of five collagen hydrogels with different collagen concentration (right) after 24 h of polymerization
(image from [64]). (B) Hydrogel structural properties as a function of network concentration. Concen-
tration dependence of the average pore size of fibrin (red) and collagen (black) gels (image from [65]).
(C) Reconstituted collagen-based hydrogels within a microfluidic chip. Maximum intensity projection
in the Z direction of a 2 mg/mL and a 4 mg/mL 3D collagen type I network structure. Fiber images
obtained with Nikon D-Eclipse C1 equipped with a 40X oil objective (image from [66]). (D) Effect of
cell encapsulation within a collagen hydrogel. 3D reconstruction of collagen fibers in the vicinities of
the cell or far from the cell (middle figures). Changes on average fiber length for the regions near the
cell and far from the cell (right) (image from [66]). Images taken with permission from publishers.
3.2. Synthesis of Hydrogels
Hydrogels for tissue engineering applications must fulfill a number criteria, such
as physical parameters (e.g., degradation and mechanics), mass transport parameters
(diffusion requirements), biological performance parameters and biological interaction
requirements for each specific application (e.g., cell adhesion) [67]. In addition, those
specifically designed to encapsulate cells need to be non-toxic, gelled without damaging
the cells, allow the diffusion of nutrients and support its handling during experiments. All
these factors have to be considered in order to create a "custom-made" biomaterial and will
determine the type of gelation utilized in hydrogel synthesis.
Hydrogels can be synthesized via various techniques, that include chemical cross-
linking, physical cross-linking, polymerization grafting, and radiation cross-linking [68].
Attending the most common gelation methods utilized in hydrogel synthesis, it is normally
distinguished between chemically or physically cross-linked hydrogels, based on the nature
of the covalent bonds made within the matrix. Stable junctions or covalent bonds control the
degree of swelling of the hydrogel based on their polymer-water relationship and the degree
of reticulation in the matrix. On the other hand, physically cross-linked hydrogels result
from ionic bonding, hydrogen bonding, physical interactions or molecular entanglements,
which are reversible by application of force or other environmental changes [69,70]. Due
to the absence of toxic cross-linking agents, physical cross-linking has gained greater
importance over the last years compared with chemical cross-linking. Nevertheless, it
is difficult to control the material properties of the hydrogel, such as gelation time, pore
size, chemical functionalization, and degradation time due to lack of a cross-linking agent
(Figure 2B,C) [71].
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3.3. Tuning Hydrogel Properties
The properties of the cellular microenvironment are critical for cellular behavior and
are dynamically regulated in living tissues. Cells sense the mechanical properties of the
matrix through the linkage between membrane receptors and ECM proteins and, therefore,
not only the matrix stiffness but also the type and concentration of anchoring proteins
available for the cell to build up adhesion complexes and the way they are linked to the
matrix or biomaterial, influence key cellular functions such as cell differentiation [72]. Fur-
thermore, migrating cells are strongly affected by the steric hindrance constraints imposed
by the surrounding ECM (e.g., pore size and porosity) [73] as well as other structural
characteristics (e.g., fiber density and orientation) [66], that dictate the way in which they
apply contractile forces, which in turn will modify the local mechanical properties of the
surrounding matrix (Figure 2D). That is why the successful use of hydrogels in these
applications relies on the ability to tune some properties, such as the degradation rate or
the mechanical properties (e.g., cross-linking nature, density or dynamics) [74].
In order to increase the mechanical properties of hydrogels, often researchers tend to
change the polymer or crosslinker concentration [75], thereby addressing the exploration of
interesting cellular responses such as the effect of spatio-temporal gradients in mechanical
properties on cell growth and migration, by using microfluidics techniques or photopoly-
merization [76]. However, changes in the crosslinker concentration modifies as well the
porosity of the gel, which in turns affects the degradation dynamic and cell behavior (an
increase of the cross-linker density causes a decreased degradation). Consequently, a trade-
off exists between the macroporosity (10–400 µm) and the mechanical strength of the
scaffold. As an alternative to improve hydrogel mechanical stability, covalent crosslinking
of hydrogels has been used, but this is not an ultimate solution given the fact that chemical
crosslinking is irreversible and may lead to the formation of toxic by-products [77,78].
A common method to control the degradation rate of hydrogels is to incorporate pep-
tides into the network that are targets for proteases. Several studies have demonstrated that
changing either the concentration of these peptides or their amino acid target sequences
(i.e., RGD) can be used to control the rate of gel degradation [79,80]. However, the hydrogel
can result in the release of polymer fragments depending on the initial network connec-
tivity or cleavage of chemical bonds, and little is known about how these degradation
strategies, which is the loss of polymer content, may affect the spreading of cells, migration
and proliferation.
4. Hydrogel-Based Bone-On-Chips
The development of organ-on-chips typically starts from a microfabrication technique,
such as mask-based photolithography, etching precise microscale pattern into photosen-
sitive materials, thus creating a mold [81]. Later, soft lithography replicates the master
pattern in the microengineered device. For organ-on-chips applications, the soft elastomer
poly(dimethylsiloxane) (PDMS) is the standard material used for the stamp, given its
optical transparency, and biocompatibility. Moreover, PDMS can restore hydrophobicity
after the stamp is bonded to a flat surface, which facilitates the filling of the culture cham-
ber with hydrogel [82]. The final device consists of transparent polymeric microchannels
where mechanical stimuli, such as laminar fluid flow, and biochemical gradients can be
applied, while tissue-tissue interfaces can be replicated [83]. Any organ-on-chip requires
one or multiple cell types and a microscale culture chamber. Hereafter, the culture chamber
designs, the hydrogels and the cellular components used in BOCs are discussed.
4.1. Culture Chamber Designs
The complexity of culture chamber designs in BOCs is intrinsically related to the com-
position of the tissue. Indeed multi-cellular and multi-tissue interaction can be modelled
within each device. In general, single channeldevices are preferred for cell migration stud-
ies, where cells can be tracked over time within the hydrogel while applying mechanical [84]
or chemical stimuli [85–87]. Microposts between channels facilitate the identification of
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the region of interests while taking multiple images over time and support the hydrogel
stability via surface tension [87,88]. Moreover, microposts separate culture chamber, thus
confining cells and hydrogels in compartments where different culturing conditions can be
applied [89].
The definition of compartments in organ-on-chips is one of the main advantage of
microengineered technologies over traditional culture techniques. By means of computer
aided design (CAD), it is possible to tune the geometry of each single channel and the way
multiple channels communicate with each other [90]. An example of effective culture cham-
ber design in BOC is the one proposed by Mei et al., who studied cancer cell extravasation
in bone tissue by creating channels for osteocytes and a lumen . In the osteocyte channel,
cells could be selectively stimulated with oscillatory fluid flow, while the lumen channel
consisted of a cylindrical hydrogel structure coated with endothelial cells and seeded with
breast cancer cells. Moreover, the distance between the osteocyte and the lumen channel
was 300 µm, to recapitulate the physiological distance between osteocytes and effectors
cells [91]. Similarly, a bone-marrow-on-chip was recently developed based on two channels
separated by a porous membrane. The two channels consisted of a hematopoietic and a
vascular compartment. The in vivo functionality of the vascular lumen was replicated by
feeding the whole chip exclusively via perfusion through the vascular compartment that
was covered with endothelial cells [16]. For the microfabrication details of organ-on-chip
devices comprising multiple cell types embedded in hydrogels, we recommend reading
the protocol developed by Shin et al. [82], Huh et al. [92] and Novak et al. [93].
Besides using channels as culture chambers, microengineered system can induce chem-
ical gradients within the culture environment. In addition, microfluidic devices facilitate
the application of independent fluid flows for different channels. Thus, a system of two ser-
pentine channels perfused by different cell culture media induced an osteo/chondrogenic
gradient within a single hydrogel. In this way, the same hydrogel-based environment
induced a differentiation gradient for MSCs mimicking the interface between bone and
cartilage [94].
4.2. Hydrogels
Given their remarkable biocompatibility and non-toxicity, natural hydrogels are of-
ten selected to imitate the native ECM in BOC systems (Table 1). The hydrogel choice
depends on the specific environment to be modeled. For example, the formation of a fibrin
matrix immediately after a bone injury makes fibrin gels a suitable model to study the
healing of bone. By embedding osteoprogenitor cells, a fibrin gel can generate a heal-
ing bone-mimicking (BMi) microenvironment and induced the functional formation of a
microvascular network [95]. Moreover, in the same project, the same microenvironment
recreates a bone inflammatory model with the addition of a macrophage-like cell line
(RAW264.7 cells).
In search of a model representing mature bone, fibrin was mixed with type I colla-
gen which increased the hydrogel stiffness and its mechanical stability [96]. Due to its
ubiquitous presence in the bone matrix, hydrogel-based BOC systems normally used type
I collagen when culturing primary Human Osteoblasts (HOBs) (Table 1). The collagen
mechanical properties varied between the different applications of the BOCs. In gen-
eral, collagen concentration was higher when the system meant to induces osteogenic
differentiation and mineralization [88,97], while it was lower when studying osteoblast
migration [84,85]. Collagen-based hydrogels have a fibrous architecture whose interaction
with the embedded cells alters both the hydrogel mechanical properties and the cellular
activity within the BOC. It has been demonstrated that collagen fiber reorientation due to
interstitial fluid flow increases osteoblasts migration [84]. Moreover, osteoblasts remodel
the collagen hydrogel with proteolytic enzymes, the metalloproteinases, which in turn
regulate cell migration through the matrix [85].
Hydrogels mechanical properties can be enhanced with composite systems. Besides
mixing with fibrin, collagen I was also mixed with Matrigel prior to load within BOC
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devices (Table 1). Given that Matrigel is a gelatinous protein mixture, a composite hydrogel
made of collagen I and Matrigel provides a variety of structural proteins and growth factors
resembling the native ECM [63]. Although the incorporation of a bioactive inorganic phase
in hydrogels has been widely investigated to boost hard tissue regeneration [98], bone
formation was never assessed in hydrogel-based BOC while incorporating calcium phos-
phates or bioglasses. However, HA nanoparticles were incorporated in fibrin hydrogels and
loaded into BOC systems and showed the inhibitory effect HA in cancer cell migration [99]
and a stimulative effect on endothelial sprouting [100]. Instead of incorporating inorganic
phases, recent hydrogel-based BOCs recreated mineralized microenvironments by combin-
ing a collagen I hydrogel with osteogenic factors [101] or by culturing osteo-differentiated
MSCs that deposited newly mineralized matrix [97].
Table 1. Selection of recent studies using hydrogel-based bone-on-chips to model physiological or pathological bone
microenvironments. Hydrogel concentrations are between brackets and expressed in mg/mL or weight/volume%. Abbrevi-
ations: hBM human bone marrow derived, MSC mesenchymal stem cell, MDA-MB-231 human mammary adenocarcinoma
cell (high invasion capacity), HUVEC human umbilical vein endothelial cell, MLO-Y4 murine osteocyte-like cell Line, OD
osteoblast-differentiated, BMSC bone marrow stromal cell, SUP-B15 acute lymphoblastic leukemia cell line, HOB primary
human osteoblasts, HS5 human bone marrow stromal cell line, DBP bone-inducing demineralized bone powder, BMP bone
morphogenetic protein, HA hydroxyapatite, SW620 human colon cancer, MKN74 human gastric cancer, LF human lung
fibroblast, ADMSC adipose-derived mesenchymal stem cell, ECM extracellular matrix.
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The selection and the number of different cell types to introduce in a BOC system
includes, but it is not limited to, cells normally residing in the bone tissue, while the inter-
action with other tissues requires the use of different cell sources. The cellular component
of the bone matrix is usually represented by osteoblasts or osteocyteswhile MSC and osteo-
clast precursors are included to study bone remodelling or to create a bone marrow niche.
MSCs are routinely obtained from bone marrow or adipose tissue, and used as osteopro-
genitor cells in organ-on-chip mimicked the mineralizing microenvironment [95,102] or
osteochondral bone formation [94]. On the other hand, MSCs were maintained in vitro to
recapitulate the bone marrow microenvironment. Indeed, once seeded in a bone-marrow-
on-chip with CD34+ cells (hematopoietic stem cells), it has supported white and red blood
cells differentiation over 4 weeks of culture while improving the maintenance of CD34+
progenitors over traditional culture methods [16] (Figure 3A). A different approach from
the traditional isolation and seeding of primary human cells has been proposed to recapit-
ulate the physiology of bone marrow. Briefly, it consisted of a prior in vivo implantation of
an hydrogel-based bone microenvironment. After 8 weeks, the hydrogel was populated by
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multiple hematopoietic cells and it was cultured in a microfluidic device after explantation
to recapitulate a hematopoietic niche in vitro. Bone-marrow-on-chips and whole mar-
row from live mice showed comparable resistance to radiation, unlike stroma-supported




Figure 3. Inducing cell differentiation in hydrogel-based bone-on-chips. (A) A vascularized human
bone marrow-on-chip was developed with optically clear poly(dimethylsiloxane) channels. In the
top channel, hematopoietic stem cells (CD34+) were seeded, while endothelial cells (EC) created a
vascular lumen in the bottom channel. After 2 weeks of in vitro culture, hematopoietic stem cells
differentiated in multiple blood cell types (magenta: erythroid lineage; yellow: megakaryocyte lin-
eage; blue: neutrophil and other haematopoietic lineages). Scale bar, 20 µm. Image adapted from [16].
(B) Collagen-based bone-on-chip modeling primary human osteoblast differentiation into osteo-
cytes. Cells increased primary protrusion length over time and exhibited dendritic morphology after
21 days of culture. Osteogenic differentiation was confirmed by an increasein alkaline phosphatase
activity and synthesis of Dental Matrix Protein 1 (DMP1). * represents statistical significance (p < 0.05).
Scale bar, 50 µm. Image adapted from [88]. Images were taken with permission from publishers.
In view of modeling the last stages of osteogenesis, HOB can be isolated from trabec-
ular or cortical bone tissue. It has been showed that HOBs cultured in BOCs experience
the specific changes in cellular morphology, protein secretion and proliferation observed
in vivo [88] (Figure 3B). Due to the technical complexity of isolating primary human osteo-
cytes from the mineralized bone, the murine osteocyte cell line MLO-Y4 was recently used
in microfluidic systems to investigate the mechano-regulatory action of osteocytes [91].
Results showed, for the first time in a microfluidic device, that mechanically stimulated
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osteocytes reduced breast cancer extravasation [91]. The use of primary human osteo-
cytes, or fully differentiated HOBs, in hydrogel-based BOCs will be critical for future
patient-specific applications.
Besides including different cell types involved in the development, growth and re-
modeling of bones, a more realistic bone microenvironment requires modeling interactions
between tissues made of those cells. For example, vascular tissue interacts with bone
forming cells and affects both bone pathology and physiology. Indeed one BOC devicewas
designed to deposit a layer of Human Umbilical Vein Endothelial Cells (HUVECs) on the
external side of the hydrogelto recreate the interface between blood vessels and the bone
matrix, and to simulate the extravasation process of cancer cells [97,104] (Figure 4). Indeed,
the use of organ-on-chips facilitates the interaction between three to four different cells
types to model the interaction between tumors, vascular and bone tissue. A few studies
include fibroblasts when mimicking a tumor microenvironement since stromal cells are
expected to nurture the tumor microenvironment and influence metastasis of the can-
cer [99,102]. Altogether those microengineered devices with endothelial cells contributed
to identify the molecular pathways involved in the extravasation of breast cancer cells
in bone [97], showed that the bone marrow microenvironment facilitates leukemia cell
survival during drug treatment [103], and generated a vascularized network inside cell
spheroids that permit to transport nutrients and cells to study metastasis [102].
Figure 4. On-chip device modeling breast cancer metastasis in the bone tissue. Microfluidic device
modeling breast cancer cell extravasation towards the bone tissue. Tri-culture system where osteo-
differentiated mesenchymal stem cells created a bone-like environment by conditioning a collagen
hydrogel. After seeding a monolayer of endothelial cells on the edge of the collagen hydrogel, breast
cancer cells were introduced and their extravasation ability was assessed. Scale bar, 50 µm. Image
adapted from [97]. Images were taken with permission from publishers.
5. Towards Personalized Bone-On-Chips
Bone not only provides structural support for the body to enable movement, but it also
serves as a major stem cells (mesenchymal and hematopoietic) and metabolic storage site
(i.e., for calcium). The diseases affecting bone have a wide spectrum of etiology but most
of them induce frailty in patients with for example higher fracture risk. The complexity
of the organ (several types of tissue, highly organised matrix) and of the symptoms make
it difficult to predict the efficiency of treatments or the osteointegration of orthopedic
implants. To recapitulate the diseases in vitro, the physical, mechanical and biochemical
microenvironment that are key elements and specific to each pathology can be varied, such
as a decreasing of the pH to study cancer metastasis [105] (Figure 5).
BOCs are an effective technology to build in vitro microenvironments resembling
the specific pathological or physiological process under investigation. The essential com-
ponents of hydrogel-based BOCs are the cellular sources, the hydrogel and the culture
chamber which have been tuned to mimic the hematopoietic niche in the bone mar-
row [16,101,103,104], cancer bone metastasis [91,95,97], or osteo/chondrogenic differentia-
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tion [88,94]. Hydrogels play an important role in engineering BOCs to mimic the specific
characteristics of the microenvironment under investigation. First, hydrogels must be
designed to encapsulate cells and gelate within the culture chamber without damaging the
embedded cells. Collagen-based hydrogels are the most common choice in BOCs as this
protein is the principal component of the mineralized bone matrix and the marrow matrix.
Bone marrow niches are commonly associated to lower collagen concentrations, with lower
mechanical properties, while an osteogenic microenvironment corresponded to higher
collagen concentrations or by incorporating HA (Table 1). Besides collagen, fibrin hydrogels
can accelerate bone healing [106], and model the early stage extracellular environment of
bone diseases such as fracture healing and cancer tumor-fibrin matrix [107]. At the same
time, the emergence of synthetic hydrogels have offered a wider control over the structural,
chemical and mechanical properties. For example, thermo-responsive hydrogel could
exponentially increase their stiffness after gelation, being an ideal model to investigate the










Figure 5. Modeling bone biology with personalized hydrogel-based bone-on-chips. Bone-on-chips
aim at replicating specific functions of the bone tissue in sophisticated in vitro microenvironments.
From a biological perspective, the variability associated with cell phenotype and bone diseases makes
it difficult for traditional models to predict the efficacy of potential therapies. Each physiological
or pathological bone process has a specific extracellular environment, which can be replicated by
using hydrogels and tuning their biochemical composition, structural and mechanical properties.
Therefore, hydrogel-based bone-on-chips offer personalized bone tissue models, where a proper
combination of complex 3D microenvironments and primary human cells can answer questions on
bone biology and test novel treatments.
Tuning and monitoring hydrogel structural properties over time can be used to model
both physiological and pathological processes of the bone tissue. For example, the bone
remodelling process has direct effects on matrix architecture and BOCs provide an innova-
tive system that requires few ressources and where osteoblasts, osteoclasts and osteocytes
can be simultaneously cultured in a 3D environment while monitoring the bone forma-
tion/resorption balance. However, the bone regeneration potential cannot only be reduced
to variations in the osteogenic activity of osteoblast/osteocyte embedded in a 3D matrix.
In order to build relevant models of bone regeneration, further research is needed to reca-
pitulate the structural complexity of the bone tissue, as well as its interaction with any other
tissue affecting the regeneration process [11]. As for pathological mechanisms, a precise
control of the hydrogel architecture could replicate trabecula thickness of single individuals,
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which is considered a risk factor for postmenopausal bone loss [47]. Thus, BOCs could
define patient-specific matrices and predict the outcome of osteoporosis based on the initial
trabecula thickness. It is then clear that BOCs can help predicting the outcome of treatments
by designing different bone characteristics with specific hydrogel composition. In addition,
each sample can be patient-specific if a small bone explant is harvested and primary human
cells extracted and seeded in a BOCs (Figure 5).
Patient-to-patient variability is a critical challenge for tissue engineering and personal-
ized therapies where patient-specific organ-on-chips offer innovative systems to predict
biological variability between individuals [12,13]. A BOC system has already compared the
osteogenic activity of bone cells isolated from different patients [88]. Thus, future studies
might determine how bone-related disorders alter the osteogenic activity of primary human
bone cells by means of controlled experimentation with patient-specific BOCs. Furthermore,
the organ-on-chip technology relies on the use of microfluidic systems to apply various
mechanical stimuli on cells where the culture condition could be monitored with microscale
and nanoscale biomedical sensors [108,109]. Indeed human tissues are characterized by
different mechanotransduction signals, thus organ-on-chips offer alternative solutions to
apply multiple mechanical and physical cues, such as shear and interstitial flow, cyclic
stretching, stiffness gradient or geometric confinement [110]. In addition, as for the bone
tissue, osteocyte regulatory role of both bone formation and resorption processes is directly
related to strains and fluid shear stresses in the lacunocanalicular network. It is know that
extracellular proteins, such as glycocalyx, bind cell receptors, such as integrins, and activate
mechanotransduction pathways by stretching the cell membrane [111]. Therefore, BOC
platforms could investigate the osteocyte mechanotransduction with a direct control on the
3D matrix where cells are embedded and on the interstitial fluid flow that replicates the
in vivo mechanical stimuli.
For future studies, BOC devices will not only be key for a precise personalized
medicine, but it will also provide a great tool to study in vitro bone mechanobiology by
applying mechanical stimuli. Therefore, BOCs can have a role in pre-clinical evaluation and
are the ideal candidate to predict the individual mechano-sensitivity in bone regeneration in
a controlled microenvironment. By reproducing around bone cells pathological conditions
with the association of mechanical stimuli and circulating levels of specific factors, such
as estrogen [44], in microfluidic devices, future studies might be capable to predict the
individual mechano-sensitivity and bone regenerative capacity in vitro in these specific
microenvironments. In conclusion, this review aims at providing essential background
and guidelines on the design of hydrogel-based BOC platforms to model bone tissue. It is
clear that the rapid advances in the organ-on-chip technology will allow to answer further
biological questions and to test therapies in vitro at a small scale and with limited resource
(cells, materials). In the near future of personalized medicine and therapies for bone
disease, those major tools will allow to assess for each individual biological response with
patient-specific BOCs that recreate clinically relevant scenarii in miniaturized devices and
that could predict the outcome of a treatment. Future development of BOCs and hydrogels
will be required to tune specifically the three microenvironments around cells (biochemical,
physical and mechanical) and to permit real-time assessment with live microscopic studies.
However, more detailed knowledge on changes at the nanolevel in the matrix of bone for
each diseases will be required to improve the composition of the hydrogels.
Author Contributions: Conceptualization, project administration, writing—original draft, review-
ing and editing G.N. and J.S.; writing—original draft, M.C.; writing—review and editing, T.V.;
Supervision J.S. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding. However authors were funded by the European
Research Council Horizon 2020 research and innovation programmes, for Gabriele Nasello by the
Marie Skłodowska-Curie grant agreement No 722535 (CuraBone project), for Jessica Schiavi by the
ERC Starting Grant MULT2D held by Ted Vaughan (No 804108), and for Mar Cóndor was funded by
the FWO fellowship 12ZR120N.
Appl. Sci. 2021, 11, 4495 16 of 20
Conflicts of Interest: The authors declare no conflict of interest.
References
1. United States Bone and Joint Initiative. The Burden of Musculoskeletal Diseases in the United States (BMUS), 3rd ed.; Rosemont, IL,
USA, 2014; p. 711. Available online: http://www.boneandjointburden.org (accessed on 1 March 2021).
2. Plannel, J.; Navarro, M. Challenges of bone repair. In Bone Repair Biomaterials; Elsevier: Amsterdam, The Netherlands, 2009;
pp. 3–24. [CrossRef]
3. Donaldson, L.J.; Reckless, I.P.; Scholes, S.; Mindell, J.S.; Shelton, N.J. The epidemiology of fractures in England. J. Epidemiol.
Community Health 2008, 62, 174–180. [CrossRef] [PubMed]
4. Buza, J. Bone healing in 2016. Clin. Cases Miner. Bone Metab. 2016. [CrossRef] [PubMed]
5. Einhorn, T.A. Enhancement of fracture-healing. J. Bone Jt. Surg. 1995, 77, 940–956. [CrossRef] [PubMed]
6. Borgström, F.; Karlsson, L.; Ortsäter, G.; Norton, N.; Halbout, P.; Cooper, C.; Lorentzon, M.; McCloskey, E.V.; Harvey, N.C.; Javaid,
M.K.; et al. Fragility fractures in Europe: Burden, management and opportunities. Arch. Osteoporos. 2020, 15, 59. [CrossRef]
7. Cramer, E.E.A.; Ito, K.; Hofmann, S. Ex vivo Bone Models and Their Potential in Preclinical Evaluation. Curr. Osteoporos. Rep.
2021, 19, 75–87. [CrossRef]
8. Caddeo, S.; Boffito, M.; Sartori, S. Tissue Engineering Approaches in the Design of Healthy and Pathological In Vitro Tissue
Models. Front. Bioeng. Biotechnol. 2017, 5. [CrossRef]
9. Boussommier-Calleja, A.; Li, R.; Chen, M.B.; Wong, S.C.; Kamm, R.D. Microfluidics: A New Tool for Modeling Cancer–Immune
Interactions. Trends Cancer 2016, 2, 6–19. [CrossRef]
10. Zhang, B.; Korolj, A.; Lai, B.F.L.; Radisic, M. Advances in organ-on-a-chip engineering. Nat. Rev. Mater. 2018, 3, 257–278.
[CrossRef]
11. Harink, B.; Le Gac, S.; Truckenmüller, R.; van Blitterswijk, C.; Habibovic, P. Regeneration-on-a-chip? The perspectives on use of
microfluidics in regenerative medicine. Lab A Chip 2013, 13, 3512. [CrossRef]
12. van den Berg, A.; Mummery, C.L.; Passier, R.; van der Meer, A.D. Personalised organs-on-chips: Functional testing for precision
medicine. Lab A Chip 2019, 19, 198–205. [CrossRef]
13. Vatine, G.D.; Barrile, R.; Workman, M.J.; Sances, S.; Barriga, B.K.; Rahnama, M.; Barthakur, S.; Kasendra, M.; Lucchesi, C.; Kerns,
J.; et al. Human iPSC-Derived Blood-Brain Barrier Chips Enable Disease Modeling and Personalized Medicine Applications. Cell
Stem Cell 2019, 24, 995–1005.e6. [CrossRef]
14. Benam, K.H.; Villenave, R.; Lucchesi, C.; Varone, A.; Hubeau, C.; Lee, H.H.; Alves, S.E.; Salmon, M.; Ferrante, T.C.; Weaver, J.C.;
et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat. Methods 2016,
13, 151–157. [CrossRef]
15. Zhang, W.; Lee, W.Y.; Siegel, D.S.; Tolias, P.; Zilberberg, J. Patient-Specific 3D Microfluidic Tissue Model for Multiple Myeloma.
Tissue Eng. Part C Methods 2014, 20, 663–670. [CrossRef]
16. Chou, D.B.; Frismantas, V.; Milton, Y.; David, R.; Pop-Damkov, P.; Ferguson, D.; MacDonald, A.; Vargel Bölükbaşı, Ö.; Joyce, C.E.;
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